In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
Monthly romosozumab
Every 6 months denosumab
Massachusetts General Hospital
Boston, Massachusetts, United States
Total hip areal bone mineral density
Change in total hip bone density between month 0 and month 12
Time frame: Month 0 to 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.